ClinicalTrials.Veeva

Menu

Deprescribing Antipsychotics: a Multiple Case Study (DEPRESC)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

Psychotic Disorder

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc.

The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments.

This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults (≥18 years)
  • Patients with a psychotic or related disorder
  • Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025

Exclusion criteria

- Patients who have expressed their opposition to participating in the study

Trial contacts and locations

1

Loading...

Central trial contact

Fabrice BERNA, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems